Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 5/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.33 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2546306 | 0.86 | PIK3CD (0.35) | ALDH1A1PIK3CDPOLB | |
| SCHEMBL2547711 | 0.84 | METAP2 (0.41) | EP300CNR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2547707 | 0.84 | METAP2 (0.41) | EP300CNR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL23341959 | 0.78 | METAP2 (0.40) | EP300CNR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12022033 | 0.77 | METAP2 (0.39) | EP300CNR1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL12037953 | 0.77 | METAP2 (0.40) | EP300CNR1ALDH1A1MAPTTNF | |
| SCHEMBL20450252 | 0.75 | METAP2 (0.43) | PIK3CDTLR7 | |
| SCHEMBL2544705 | 0.70 | METAP2 (0.44) | PIK3CD | |
| SCHEMBL2544713 | 0.70 | METAP2 (0.44) | PIK3CD | |
| SCHEMBL19254372 | 0.67 | METAP2 (0.42) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846694-B2 | Pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | MERCK PATENT GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263561-A1 | Novel pyrrolidone derivatives for use as MetAP-2 inhibitors | METAP2, METAP1, ENPEP | EP300 2811/4885CNR1 4177/4885ALDH1A1 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.